iRhythm vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

iRhythm Technologies Inc (IRTC)

Q3 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

August 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Latest16 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.